Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Lymphoid 1

Conditions

Recurrence 1Mesothelioma, Malignant 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 454Magnetic Resonance Spectroscopy 347pembrolizumab 289Biopsy 244Carboplatin 230Cisplatin 194Cyclophosphamide 186Paclitaxel 164Nivolumab 154Gemcitabine 151Radiotherapy 125Bevacizumab 124Dexamethasone 113fludarabine 100Pemetrexed 99Fluorouracil 94Doxorubicin 92durvalumab 91Radiation 91Docetaxel 91venetoclax 89Rituximab 88Oxaliplatin 88atezolizumab 87Leucovorin 79Capecitabine 76Prednisone 75Lenalidomide 70Etoposide 69X-Rays 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Combined Modality Therapy × 30 days × Clear all
NCT07610616 2026-05-28

Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids

Guangzhou Institute of Respiratory Disease

Recruiting
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06251310 2026-05-08

SW-682 in Advanced Solid Tumors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Recruiting
186 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡